[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports a purchase of 2,318,700 ordinary shares under the second tranche of its share buyback programme. The trades occurred on the London Stock Exchange/CBOE (UK)/CXE on 25 September 2025 with reported trade price points shown as 329.7000, 325.9000 and a weighted average of 327.8536. The Company intends to hold the purchased shares as treasury shares. After settlement, registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 38,908,103 are held as treasury shares, leaving 8,913,445,545 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the Company website.

Positive

• Executed buyback of 2,318,700 shares under the second tranche of the announced programme
• Purchased shares will be held as treasury shares, with the company explicitly stating intention
• Updated registered capital and voting share counts provided, allowing shareholders to determine notification thresholds
• Full trade breakdown published via RNS and the company website for transparency

Negative

• None.

Insights

Securities Analyst

TL;DR: Haleon executed a tranche of its announced buyback, reducing outstanding voting shares and adding treasury stock.

The announcement confirms execution of 2,318,700 shares purchased under the second tranche of the buyback programme, with trade data published for transparency. Retaining the shares as treasury stock means they are not cancelled and remain part of registered capital but are excluded from voting rights totals. The filing provides updated counts of registered capital, treasury shares, and voting shares, and directs investors to a full trade breakdown via RNS and the company website. This is a routine corporate action consistent with share repurchase programmes designed to manage capital structure.

Corporate Governance Expert

TL;DR: The company disclosed purchase details and updated voting share totals, meeting Market Abuse Regulation disclosure norms.

The Form 6-K furnishes required transparency under the Market Abuse Regulation by confirming the volume of shares bought, the intention to hold them as treasury shares, and the updated counts for registered capital and voting shares. The filing references an external full trade breakdown, fulfilling the disclosure obligation to allow shareholders to assess notification thresholds under the FCA's rules. The information is procedural and complies with public disclosure standards for buybacks.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	26 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

26 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 2,318,700 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	25 September 2025	25 September 2025	25 September 2025
Number of Shares purchased:	2,318,700	-	-
Highest price paid per Share (p):	329.7000	-	-
Lowest price paid per Share (p):	325.9000	-	-
Volume weighted average price paid per Share (p):	327.8536	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 38,908,103 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,913,445,545 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/9003A_1-2025-9-25.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 26, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLN) buy under the second tranche of the buyback?

The Company purchased 2,318,700 ordinary shares under the second tranche of its buyback programme.

Will Haleon cancel the repurchased shares or hold them as treasury shares?

The Company intends to hold the purchased shares as treasury shares.

What are Haleon's updated voting share totals after this buyback?

Following settlement, there are 8,913,445,545 ordinary shares with voting rights.

Where can I find the full breakdown of the individual trades?

A full breakdown is available at the RNS link provided in the announcement and on www.haleon.com/investors.

What is Haleon's registered share capital after the purchase?

Registered share capital is 8,952,353,648 ordinary shares of £0.01 each.